Marinus Pharmaceuticals Stock Price - MRNS

0.04 (1.40%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Marinus Pharmaceuticals Inc MRNS NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.02 0.7% 2.86 2.60 2.92 2.72 2.84 20:00:00
Bid Price Ask Price Spread Spread % News
2.70 2.95 0.25 8.47% - 1
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
4,985 1,317,866 $ 2.81 $ 3,708,140 1,072,435 0.77 - 5.40
Last Trade Time Type Quantity Stock Price Currency
19:30:11 formt 500 $ 2.90 USD

Marinus Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 247.39M 86.50M $ -36.73M -0.90 - 86.00M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Marinus Pharmaceuticals News

Loading Messages....

Latest MRNS Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical MRNS Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week2.303.092.232.812,271,1520.5624.35%
1 Month2.063.091.992.461,037,8030.8038.83%
3 Months1.343.091.032.091,860,0921.52113.43%
6 Months1.,558,6461.78164.81%
1 Year4.345.400.772.221,191,861-1.48-34.1%
3 Years1.3010.540.774.081,070,2991.56120.0%
5 Years11.3420.720.773.70820,467-8.48-74.78%

Marinus Pharmaceuticals Description

Marinus Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.

Your Recent History
Marinus Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.